New Medicine Service costeffective in England

New Medicine Service costeffective in England PharmacoEconomics & Outcomes News 784, p25 - 12 Aug 2017 New Medicine Service cost effective in England The English community pharmacy New Medicine Service (NMS) for patients initiating new treatment for a chronic condition appears to be cost effective, according to findings of a study published in PharmacoEconomics. Markov models for diseases targeted by the NMS (hypertension, type 2 diabetes mellitus, chronic obstructive pulmonary disease, asthma and antiplatelet regimens) were used to evaluate the impact of the NMS on patient adherence and the cost effectiveness of the NMS compared with normal practice, from the perspective of NHS England over a lifetime time horizon. The models were populated with data from a 10-week randomised controlled trial in a trial in 504 patients. Overall, the NMS was estimated to gain a mean of 0.04 additional QALYs per patient compared with ** – ), and normal practice, at a reduced cost ( £139 therefore dominated (more effective and less costly) normal practice. Estimated incremental cost- effectiveness ratios ranged from –£44 614 per QALY gained for beclometasone to £1845 per QALY gained for tiotropium bromide. The NMS had a 96.7% probability of being cost effective compared with normal practice at a willingness-to-pay threshold of £20 000 per QALY gained. "Our study suggests that the NMS increased patient medicine adherence compared with normal practice, which translated into increased health gain at reduced overall cost," concluded the authors. "From inception of the NMS to the end of August 2016, 3.59 million consultations have been claimed for with over 820,000 in the year 2015/16. From the results of this economic evaluation, this suggests £75.4 million short-term savings to the NHS, £517.6 million long-term cost savings to the NHS and 179,500 QALYs gained," they said. * National Health Service ** 2014 British pounds Elliott RA, et al. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice. PharmacoEconomics : 3 Aug 2017. Available from: URL: http:// doi.org/10.1007/s40273-017-0554-9 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

New Medicine Service costeffective in England

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/new-medicine-service-costeffective-in-england-bzXUH7X0XZ
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4236-9
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p25 - 12 Aug 2017 New Medicine Service cost effective in England The English community pharmacy New Medicine Service (NMS) for patients initiating new treatment for a chronic condition appears to be cost effective, according to findings of a study published in PharmacoEconomics. Markov models for diseases targeted by the NMS (hypertension, type 2 diabetes mellitus, chronic obstructive pulmonary disease, asthma and antiplatelet regimens) were used to evaluate the impact of the NMS on patient adherence and the cost effectiveness of the NMS compared with normal practice, from the perspective of NHS England over a lifetime time horizon. The models were populated with data from a 10-week randomised controlled trial in a trial in 504 patients. Overall, the NMS was estimated to gain a mean of 0.04 additional QALYs per patient compared with ** – ), and normal practice, at a reduced cost ( £139 therefore dominated (more effective and less costly) normal practice. Estimated incremental cost- effectiveness ratios ranged from –£44 614 per QALY gained for beclometasone to £1845 per QALY gained for tiotropium bromide. The NMS had a 96.7% probability of being cost effective compared with normal practice at a willingness-to-pay threshold of £20 000 per QALY gained. "Our study suggests that the NMS increased patient medicine adherence compared with normal practice, which translated into increased health gain at reduced overall cost," concluded the authors. "From inception of the NMS to the end of August 2016, 3.59 million consultations have been claimed for with over 820,000 in the year 2015/16. From the results of this economic evaluation, this suggests £75.4 million short-term savings to the NHS, £517.6 million long-term cost savings to the NHS and 179,500 QALYs gained," they said. * National Health Service ** 2014 British pounds Elliott RA, et al. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice. PharmacoEconomics : 3 Aug 2017. Available from: URL: http:// doi.org/10.1007/s40273-017-0554-9 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off